About Flamel Technologies
Flamel Technologies is a Healthcare company based in Venissieux (France) founded in 1990 by Gerard Soula, and was acquired by Recipharm in November 2014. Formulation drug delivery company developing drugs for anaesthesia, CNS, respiratory diabetes disorders. Flamel Technologies has completed 1 acquisition, including FSC Pediatrics. Its chief executive, as recorded, is Gerard Soula. Its focus areas include Diversified Pharmaceuticals.
Company details
Flamel Technologies is a specialty pharmaceutical company focussed in the formulation development and drug delivery to develop pharmaceutical products. It currently has 3 drugs in the USA for anesthesia namely Bloxiverz (neostigmine methylsulfate injection), Vazculep (phenylephrine hydrochloride injection) and Akovaz (ephedrine sulfate). Using its proprietary drug delivery platforms Micropump (oral sustained release microparticles platform), LiquiTime (a Micropump-derivative platform for liquid oral products) and Trigger Lock (a Micropump-derivative platform for abuse-resistant opioids), it is also developing its pipeline for CNS respiratory disorders which include sodium oxybate, an extended-release of liquid medicines such as ibuprofen and guaifenesin and also working on the delivery of exenatide utilizing the Medusa technology for diabetes. It acquired Eclat Pharmaceuticals FSC Pediatrics in March 2012 February 2016 respectively.
- Headquarters Venissieux, France
- Founders Gerard Soula
- Stage Acquired
- SectorsHealthcare
- Website flamel.com
- Social LinkedIn
- Acquired by Recipharm (Nov 2014)
Funding Insights of Flamel Technologies
- Total Rounds 1
- Last Round Debt – Venture — $15M
- First Round $15M
(Feb 2013)
- Investors Count 1
All 1 funding rounds of Flamel Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2013 | $15M | Debt – Venture | – | – |
2 investors in total: 2 institutional.
Investors in Flamel Technologies
Flamel Technologies has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Recipharm and Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Pharmaceutical development and manufacturing services are offered contractually. | 1995 | recipharm.com | Jordbro, Sweden |
Investor details for Flamel Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Flamel Technologies
2 people are tracked at Flamel Technologies (2 in leadership).
| Name | Role | Group |
|---|---|---|
Gerard Soula | Founder & CEO | Leadership |
Stephen H Willard | CEO | Leadership |
Complete people profiles for Flamel Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Flamel Technologies
Flamel Technologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include FSC Pediatrics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pediatric healthcare services are provided in Charlotte. | fscpediatrics.com | Charlotte, United States | 2004 | Feb 2016 | •••• |
Complete acquisition details for Flamel Technologies
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Flamel Technologies
5 dated milestones of Flamel Technologies across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Flamel Technologies is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $15.0M.
- Exit Acquired by Recipharm.
- Acquisition Acquires FSC Pediatrics.
Web traffic of Flamel Technologies
Websites that share an audience with Flamel Technologies (flamel.com).
Websites whose visitors overlap most with Flamel Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
capsulution.com | capsulution.com | 100% | #3,311,802 | – | |
| hybridplastics.com | 100% | 1.8K | #6,871,765 | View details | |
| firstnano.com | 100% | View details | |||
bionanomatrix.com | bionanomatrix.com | 100% | – | ||
| atdbio.com | 100% | 29.3K | #886,988 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Flamel Technologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Flamel Technologies
Flamel Technologies was founded in 1990 and raised its 1st funding round 23 years after it was founded.
Flamel Technologies is headquartered in Venissieux, France. It is registered at Venissieux, Auvergne-rhone-alpes, France.
Gerard Soula is the CEO of Flamel Technologies, as recorded in our data. They have also founded this company.
Flamel Technologies is a specialty pharmaceutical company focussed in the formulation development and drug delivery to develop pharmaceutical products. It currently has 3 drugs in the USA for anesthesia namely Bloxiverz (neostigmine methylsulfate injection), Vazculep (phenylephrine hydrochloride injection) and Akovaz (ephedrine sulfate). Using its proprietary drug delivery platforms Micropump (oral sustained release microparticles platform), LiquiTime (a Micropump-derivative platform for liquid oral products) and Trigger Lock (a Micropump-derivative platform for abuse-resistant opioids), it is also developing its pipeline for CNS respiratory disorders which include sodium oxybate, an extended-release of liquid medicines such as ibuprofen and guaifenesin and also working on the delivery of exenatide utilizing the Medusa technology for diabetes. It acquired Eclat Pharmaceuticals FSC Pediatrics in March 2012 February 2016 respectively.
Flamel Technologies has made 1 acquisition, including FSC Pediatrics.
Yes. Flamel Technologies was acquired by Recipharm in November 2014.